- 1、本文档共95页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
* 1415 – Danne et al. Data on File This was a multi-centre, randomised, open-label, 24-week cross-over study (two 12-week periods) safety and efficacy study. There was no washout-period between the treatments. After randomisation, during the first 2 weeks (of 12 weeks), insulin doses were titrated for dose optimisation. After 12 weeks, patients transferred to the alternative meal-time insulin. After crossover, there was a further 2-week titration period. * 1415 – Danne et al. Data on File This slide shows mean seven-point blood glucose profiles for postprandial NovoRapid? and preprandial HI. There were no significant differences between the treatments. * 1415 – Danne et al. Data on File Glycaemic control (changes in HbA1c and fructosamine) showed no significant differences between treatments The number of hypoglycaemic episodes (a rate of 140 episodes per year) was high in both groups in this study. (The rate in a recent study of biphasic NovoRapid? versus HI in children and adolescents was approximately 50 episodes per year1). The number of adverse events was similar with both treatments. There were 112 adverse events (55 with NovoRapid? , 57 with HI). The majority of adverse events were mild or moderate. There were three serious adverse events (all with HI). They were not considered to be treatment-related. No deaths occurred. 1. Mortensen et al. Pediatr Diabetes. 2006 Feb;7(1):4-10. (study 1240 ) * 1415 – Danne et al. Data on File Satisfaction to continue with NovoRapid? was significantly greater than with HI (p = 0.045). There was a trend to preference for recommending NovoRapid? treatment to others compared with HI (p = 0.051). * 1200 – Danne et al. Diabetes Care. 2003 Aug;26(8):2359-64. This study demonstrated the feasibility of mealtime dosing of NovoRapid? without compromising glycaemic control in adolescents and children. * 从上表中我们可以看出三种胰岛素的等电点不同,诺和锐的等电点最低, 这意味着只有在更低的pH值时,诺和锐才能形成沉淀 ,也说明了诺和锐在泵中出现结晶的 可能性会低于其它产品。 * 这时另一个体外研究的结果: 横坐标为pH值,纵坐标为沉淀的百分比。 测定三种产品
您可能关注的文档
最近下载
- 化学品安全管理制度、岗位责任制.doc VIP
- Unit 4(复习课件)五年级英语上册(译林版三起).ppt
- 江苏省南京市六校联合体2023-2024学年高三上学期10月联合调研物理试题及答案解析.docx
- 生猪生态养殖项目可行性研究报告.doc
- 2024新疆生产建设兵团第十师北屯市医共体招聘编制备案制人员76人笔试备考题库及答案解析.docx
- 幼儿教科研课题:幼儿园数学教育途径与指导策略的研究结题工作报告.doc VIP
- 蝶变英语3500词电子版.pdf VIP
- 2023年成都设计咨询集团有限公司人员招聘考试题库含答案解析.docx
- 2021秋国家开放大学电大《毛泽东思想和中国特色社会主义体系概论》大作业终结性三套试题(含答案).pdf
- 高中英语_The Sky Railway教学课件设计.ppt
文档评论(0)